Semaglutide product description — GLP-1 receptor agonist peptide
Semaglutide
A synthetic peptide engineered to resist rapid enzymatic breakdown, enabling once-weekly subcutaneous dosing or once-daily oral administration. Purity >99% · Double lab tested.
Brand names
Injectable
Oral
Injectable
Approved indications
- Glycemic control in type 2 diabetes
- Cardiovascular risk reduction
- Chronic weight management
- Kidney disease progression (T2D)
- Non-cirrhotic MASH (Wegovy)
Mechanism of action
Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, keeping hypoglycemia risk low during monotherapy.
Suppresses inappropriate glucagon release from alpha cells, reducing hepatic glucose output.
Slows the rate at which the stomach empties, prolonging fullness after meals.
Acts on hypothalamus and brainstem receptors to reduce hunger and the rewarding qualities of palatable food.
Key clinical trials
~2.4% (placebo)
Adverse effects & safety
Most common effects are gastrointestinal and dose-dependent: nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Pancreatitis and gallbladder disease
- Acute kidney injury (often linked to GI-related dehydration)
- Diabetic retinopathy complications
- Elevated hypoglycemia risk when combined with insulin or sulfonylureas
Boxed warning: risk of thyroid C-cell tumors based on rodent studies. Contraindicated in patients with medullary thyroid carcinoma history or MEN-2. Also contraindicated in pregnancy.




Reviews
There are no reviews yet.